UK researchers released first ever national strategy for cancer vaccine development, focusing on pre-cancer biology & tumor-specific proteins to create preventive vaccines. They highlight mRNA tech’s potential for personalized treatments, aligning with GSK & Oxford’s £50M cancer vaccine initiative
